Continuous Glucose Monitoring Market Size & Growth Forecast 2027–2036, By Segments (Component, End Use), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape

Market Size and Growth Outlook

Continuous Glucose Monitoring Market size was valued at USD 13.87 Billion in 2026 and is projected to grow at 16.95% CAGR from 2027 to 2036, reaching USD 66.39 Billion by 2036. The industry revenue for 2027 is estimated at USD 15.9 Billion.

• Base Year Value (2026): USD 13.87 Billion
• CAGR (2027-2036): 16.95%
• Forecast Year Value (2036): USD 66.39 Billion
• Historical Data Period: 2022-2026
• Largest Region: North America
• Forecast Period: 2027-2036

Continuous Glucose Monitoring Market Intelligence Snapshot:

• Regional Market Dynamics:

  • North America accounted for 49.93% in 2025, reflecting strong adoption of advanced diabetes technologies, developed healthcare infrastructure, and integration with digital health platforms.
  • Asia Pacific is expanding fastest as diabetes prevalence rises and healthcare access, medical technology infrastructure, specialized care, and awareness of advanced monitoring improve.

• Segment Momentum:

  • Sensors accounted for 53.53% of the market in 2025 and remain central due to real-time glucose measurement, improved accuracy, longer wear duration, and enhanced patient comfort.
  • Home care settings held a 79.38% share in 2025 as patients increasingly prefer convenient self-monitoring, remote care support, and connected digital health solutions.

• Market Expansion Drivers:

  • Rising global diabetes prevalence driving continuous glucose monitoring device adoption
  • Government awareness initiatives accelerating uptake of diabetes monitoring solutions
  • Integration of AI-enabled analytics improving real-time glucose trend prediction capabilities

• Leading Market Participants:

  Major players in the continuous glucose monitoring market include Abbott Laboratories (United States), Dexcom, Inc. (United States), Medtronic plc (Ireland), F. Hoffmann-La Roche Ltd. (Switzerland), Senseonics Holdings, Inc. (United States), Sinocare Inc. (China), A. Menarini Diagnostics S.r.l. (Italy), i-SENS, Inc. (South Korea), Medtrum Technologies Inc. (China), Zhejiang POCTech Co., Ltd. (China)

Unlock Complete Insights

Global Market Forecast Snapshot:

• Market Outlook:

  • 2026 Market Size: USD 13.87 Billion
  • 2027 Estimated Market Size: USD 15.9 Billion
  • Projected Market Size: USD 66.39 Billion by 2036
  • Growth Forecasts: 16.95% CAGR (2027-2036)

• Regional and Segment Outlook:

  • Leading Regional Market: North America
  • High-Growth Regional Hub: Asia Pacific
  • Core Revenue Segment: Sensors (Component) | Home Care Settings (End Use)
  • Emerging Opportunity Segment: Sensors (Component) | Home Care Settings (End Use)

Market Growth Drivers and Industry Trends

Rising global diabetes prevalence driving continuous glucose monitoring device adoption

The increasing number of individuals requiring long-term glucose management is strengthening demand for technologies that provide continuous and convenient monitoring. The continuous glucose monitoring market growth is driven by the growing need for real-time glucose tracking, enabling users and healthcare providers to better understand glucose fluctuations and make more informed treatment decisions. Continuous monitoring also reduces dependence on frequent conventional testing methods while supporting personalized disease management across diverse patient groups requiring ongoing glycemic assessment.

Government awareness initiatives accelerating uptake of diabetes monitoring solutions

Public health campaigns promoting diabetes screening, early diagnosis, and disease management are encouraging broader acceptance of advanced monitoring technologies. These initiatives will drive the continuous glucose monitoring market growth by improving awareness of the benefits of continuous glucose tracking among patients, caregivers, and healthcare professionals. Government-led educational programs, reimbursement support in applicable healthcare systems, and community outreach efforts further contribute to increased utilization of modern monitoring solutions within routine diabetes care.

Integration of AI-enabled analytics improving real-time glucose trend prediction capabilities

Advances in artificial intelligence are enhancing the ability of glucose monitoring systems to interpret continuously generated data and identify meaningful patterns. Within the continuous glucose monitoring market, AI-enabled analytics improve the value of monitoring devices by delivering predictive insights, recognizing emerging glucose trends, and supporting timely therapeutic decisions. Intelligent algorithms also assist users through personalized notifications, improved data visualization, and adaptive analysis that transforms raw glucose readings into more actionable clinical information.

Growth Driver Assessment Framework
Growth Driver	Impact On CAGR	Regulatory Influence	Geographic Relevance	Adoption Rate	Impact Timeline
Rising global diabetes prevalence driving continuous glucose monitoring device adoption	2.1%	High	North America, Europe, Asia Pacific	High	Near Term
Government awareness initiatives accelerating uptake of diabetes monitoring solutions	1.7%	High	North America, Europe	High	Near Term
Integration of AI-enabled analytics improving real-time glucose trend prediction capabilities	1.5%	Moderate	North America, Asia Pacific	Medium	Mid Term

Regional Demand Dynamics

North America (Largest Region) vs Asia Pacific (Fastest-Growing Region)

North America accounted for 49.93% of the continuous glucose monitoring market in 2026, reflecting strong adoption of advanced diabetes management technologies, developed healthcare infrastructure, and high awareness of continuous glucose monitoring among patients and healthcare professionals. The growing emphasis on proactive disease management and real-time glucose monitoring is encouraging a shift away from conventional intermittent testing toward connected monitoring solutions. Favorable access to diabetes care, expanding use of digital health technologies, and increasing integration of glucose data with mobile and remote-care platforms are further supporting adoption. In addition, the growing focus on personalized treatment and improved patient engagement is strengthening the role of continuous monitoring in long-term diabetes management.

Asia Pacific is projected to witness the fastest growth in the continuous glucose monitoring market, supported by the increasing prevalence of diabetes, improving healthcare access, and growing awareness of advanced glucose management technologies. Expanding urban populations and changing lifestyles are increasing the need for effective chronic disease management, while healthcare systems are gradually adopting digital and connected monitoring tools. Greater availability of specialized diabetes care and improving medical technology infrastructure are also making continuous monitoring more accessible to a broader patient population. Moreover, government efforts to strengthen chronic disease management and increasing interest in remote healthcare are expected to encourage wider adoption of continuous glucose monitoring solutions across the region.

No card data available for this language/report.

Segment Leadership and Growth Trends

 

Component Segment Analysis: Sensors (Largest & Fastest-Growing Segment)

The sensors segment dominated the continuous glucose monitoring market with a share of 53.53% in 2026 and also emerged as the fastest-growing component segment. Sensors form the core of continuous glucose monitoring systems by enabling real-time glucose measurement and providing the data required for accurate diabetes management. Continuous advancements in sensor accuracy, wear duration, and patient comfort have significantly improved user adoption, making sensors the most critical component within the ecosystem. The segment’s growth is further supported by increasing demand for personalized healthcare and continuous disease monitoring solutions. Rising prevalence of diabetes, growing awareness of proactive glucose management, and ongoing innovation in minimally invasive and user-friendly sensor technologies are strengthening demand. As healthcare providers and patients increasingly prioritize continuous monitoring over traditional testing methods, the sensor segment is expected to maintain its leading position.

End Use Segment Analysis: Home Care Settings (Largest & Fastest-Growing Segment)

In the continuous glucose monitoring market, the home care settings segment held the largest share of 79.38% in 2026 and was also the fastest-growing end-use segment. The widespread adoption of continuous glucose monitoring devices in home environments is driven by the convenience of self-monitoring and the ability to access real-time glucose data without frequent visits to healthcare facilities. Patients increasingly prefer home-based disease management solutions that support greater independence and improved quality of life. The segment is also benefiting from broader healthcare trends emphasizing remote patient monitoring and decentralized care delivery. Integration of continuous glucose monitoring systems with mobile applications, digital health platforms, and connected healthcare tools has enhanced accessibility and user engagement. These developments, combined with increasing awareness of diabetes management and preventive healthcare, continue to accelerate adoption within home care settings.

Report Segmentation
Segment	Sub-Segment	Largest Segment	Fastest Growing Segment
Component	Transmitters, Sensors, Receivers	Sensors	Sensors
End Use	Hospitals, Home Care Settings, Diagnostic Centres and Clinics, Others	Home Care Settings	Home Care Settings

Competitive Landscape and Market Positioning

Top players in the continuous glucose monitoring market:

1. Abbott Laboratories (United States)
2. Dexcom, Inc. (United States)
3. Medtronic plc (Ireland)
4. F. Hoffmann-La Roche Ltd. (Switzerland)
5. Senseonics Holdings, Inc. (United States)
6. Sinocare, Inc. (China)
7. A. Menarini Diagnostics S.r.l. (Italy)
8. i-SENS, Inc. (South Korea)
9. Medtrum Technologies, Inc. (China)
10. Zhejiang POCTech Co., Ltd. (China)

Continuous glucose monitoring market competition is moving toward a broader race for accessibility, user experience, and integration with connected healthcare ecosystems. Device developers are focusing on improving convenience, accuracy, and seamless data sharing to support more personalized diabetes management approaches. As adoption expands beyond traditional clinical settings, competitive differentiation increasingly depends on creating solutions that fit everyday patient routines while enabling healthcare providers to make better-informed treatment decisions through continuous insights.

Industry Development/News

Company Name	Date	Key Development
ALR Technologies	Jun-26	ALR Technologies entered into a letter of intent to acquire 100% of CGM Medical Technology Singapore and the assets of CGM Medical Technology Shenzhen in a transaction valued at $45 million plus 200 million shares, strengthening its market positioning within the continuous glucose monitoring sector.
Signos	May-26	Signos secured $20 million in funding from strategic participants including Dexcom, GV, and Blue Cross Blue Shield of Alabama, while establishing a commercial partnership with Dexcom to offer its glucose-informed weight management platform through Dexcom’s direct-to-consumer Stelo platform.
OSR Holdings	Oct-25	OSR Holdings completed the acquisition of Woori IO, securing needle-free continuous glucose monitoring technology and expanding its competitive footprint in the growing CGM market landscape.
Abbott	Nov-24	Abbott inaugurated a new continuous glucose monitoring sensor manufacturing facility in Ireland as part of a $465 million capital investment, significantly expanding production capacity for FreeStyle Libre 3 sensors to meet growing global demand.
Oura	Nov-24	Oura received a $75 million strategic investment from Dexcom as part of a collaborative initiative aimed at integrating advanced smart ring applications with future continuous glucose monitoring capabilities and broader healthcare monitoring solutions.
ŌURA	Sep-24	ŌURA acquired Veri, a specialist in metabolic health and continuous glucose monitoring, expanding its digital health ecosystem and incorporating specialized metabolic insight expertise into its wearable product portfolio.
Trinity Biotech	Feb-24	Trinity Biotech acquired Waveform Technologies' continuous glucose monitoring assets for $12.5 million and partnered with Bayer to commercialize a CGM biosensor in China and India, accelerating its strategic expansion into wearable biosensor technologies.